This article is more than 5 years old. Information may no longer be current.
Pediatric uveitis inflammation control required tight classification, collaboration
Click Here to Manage Email Alerts
Strict etiology classifications and close cooperation between pediatric rheumatologists and ophthalmologists contributed significantly to early inflammation control and long-term prognosis of pediatric uveitis, according to a retrospective data analysis.
Researchers at Lausanne University Hospital in Switzerland evaluated the demographics, etiologies, complications, treatments and visual prognoses of pediatric uveitis patients (median age, 9 years) who initially presented between January 2000 and December 2009.
Using the International Uveitis Study Group classification, 79 children (39 girls) were classified based on inflammation location. Inflammatory (69.6%) and infectious (30.4%) etiology groups were created. All patients were given a full ophthalmic examination, and systemic diseases were diagnosed by a pediatric rheumatologist. Median follow-up was 1.8 years.
The primary diagnoses were idiopathic uveitis (34.2%), juvenile idiopathic arthritis-related uveitis (22.8%) and toxoplasmic retinochoroiditis (15.2%).
Fifty-one patients had involvement in both eyes and the course was acute in 30.4%, chronic in 60.8% and recurrent in 8.9%.
Compared with all patients, anterior uveitis patients (39.2%) were younger at disease-onset (median age 4.6 vs. 9 years). Intermediate uveitis occurred in 32.9%, posterior in 22.8% and panuveitis in 5.1% of cases.
“In comparison with previous series, our study shows a higher use of systemic treatments together with less complications and better visual outcome,” the researchers wrote. “These results emphasize the importance of early aggressive treatment for better long-term visual prognosis.”
Patient visual acuity (VA), measured during the last follow-up visit, was at least 8/10 in 72% of all eyes with a measureable VA. The most common severe complications were cataract (8%), ocular hypertension/glaucoma (8%) and macular fibrosis (4%).
Fifty-six percent of patients with inflammatory uveitis were given systemic steroids, and 24% were treated with biologics.
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts